31 May 2023
CAP-XX Limited
("CAP-XX" or the "Company")
Total Voting Rights
CAP-XX Limited, a world leader in the design and manufacture of supercapacitors and energy management systems, confirms that the Company's issued ordinary share capital as at the date of this announcement comprises 586,771,204 ordinary shares of no par value, with one voting right each. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company is 586,771,204.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
For further information contact:
CAP-XX Limited |
Tel: + 61 (0) 2 9428 0139 |
|
Patrick Elliott (Non-Executive Chairman) Lars Stegmann (CEO) | |
Allenby Capital - Nominated Adviser & Joint Broker |
Tel: +44 (0) 20 3328 5656 |
David Hart / Piers Shimwell (Corporate Finance) | |
Cenkos Securities plc (Joint Broker) |
Tel: +44 (0) 20 1220 6939 |
Neil McDonald / Pearl Kellie | |
Kreab (Financial PR) |
Tel: +44 (0) 20 7074 1800 |
Robert Speed |
More information is available at www.cap-xx.com
Notes to Editors:
CAP-XX (LSE: CPX) is a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and to an increasing extent, in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDTVRSDEFFFEDSESI